

Benjamin K Hodnett

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5418791/publications.pdf>

Version: 2024-02-01

58
papers

2,085
citations

186265
28
h-index

233421
45
g-index

59
all docs

59
docs citations

59
times ranked

2289
citing authors

#	ARTICLE	IF	CITATIONS
1	Mechanistic and Structural Features of Protein Adsorption onto Mesoporous Silicates. <i>Journal of Physical Chemistry B</i> , 2002, 106, 7340-7347.	2.6	256
2	Methodology for the Immobilization of Enzymes onto Mesoporous Materials. <i>Journal of Physical Chemistry B</i> , 2005, 109, 19496-19506.	2.6	176
3	Achieving Continuous Manufacturing: Technologies and Approaches for Synthesis, Workup, and Isolation of Drug Substance May 20 th –21, 2014 Continuous Manufacturing Symposium. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 781-791.	3.3	129
4	Influence of pH and ionic strength on the adsorption, leaching and activity of myoglobin immobilized onto ordered mesoporous silicates. <i>Journal of Molecular Catalysis B: Enzymatic</i> , 2007, 49, 61-68.	1.8	89
5	Adsorption and Activity of Proteins onto Mesoporous Silica. <i>Catalysis Letters</i> , 2003, 85, 19-23.	2.6	87
6	Examining Solution and Solid State Composition for the Solution-Mediated Polymorphic Transformation of Carbamazepine and Piracetam. <i>Crystal Growth and Design</i> , 2012, 12, 1925-1932.	3.0	81
7	Kinetic studies of secondary alcohol photo-oxidation on ZnO and TiO ₂ at 348 K studied by gas-chromatographic analysis. <i>Journal of the Chemical Society Faraday Transactions I</i> , 1981, 77, 2777.	1.0	62
8	A comparative study of the use of powder X-ray diffraction, Raman and near infrared spectroscopy for quantification of binary polymorphic mixtures of piracetam. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 63, 80-86.	2.8	62
9	Solubility of Form III Piracetam in a Range of Solvents. <i>Journal of Chemical & Engineering Data</i> , 2010, 55, 5314-5318.	1.9	59
10	Effect of Amino Acid Additives on the Crystallization of L-Glutamic Acid. <i>Crystal Growth and Design</i> , 2005, 5, 593-597.	3.0	54
11	Relative Stabilities of the Five Polymorphs of Sulfathiazole. <i>Crystal Growth and Design</i> , 2012, 12, 2825-2835.	3.0	51
12	Solution Mediated Polymorphic Transformation: Form II to Form III Piracetam in Ethanol. <i>Crystal Growth and Design</i> , 2012, 12, 6151-6157.	3.0	48
13	Solution-Mediated Polymorphic Transformation: Form II to Form III Piracetam in Organic Solvents. <i>Crystal Growth and Design</i> , 2014, 14, 3967-3974.	3.0	46
14	Solid-State Transformations of Sulfathiazole Polymorphs: The Effects of Milling and Humidity. <i>Crystal Growth and Design</i> , 2013, 13, 3404-3413.	3.0	45
15	Investigation into the Mechanism of Solution-Mediated Transformation from FI to FIII Carbamazepine: The Role of Dissolution and the Interaction between Polymorph Surfaces. <i>Crystal Growth and Design</i> , 2013, 13, 1861-1871.	3.0	41
16	Surface species during the crystallization of VOHPO ₄ ·xH ₂ O. <i>Journal of Catalysis</i> , 2004, 227, 270-281.	1.2	40
17	Preparation and use of a mesoporous silicate material for the removal of tetramethyl ammonium hydroxide (TMAH) from aqueous solution. <i>Journal of Chemical Technology and Biotechnology</i> , 2001, 76, 1216-1222.	3.2	37
18	Investigation of the Solid-State Polymorphic Transformations of Piracetam. <i>Crystal Growth and Design</i> , 2012, 12, 6223-6233.	3.0	37

#	ARTICLE	IF	CITATIONS
19	Stability of MCM-48 in aqueous solution as a function of pH. <i>Microporous and Mesoporous Materials</i> , 2003, 63, 53-57.	4.4	36
20	Extraction and Purification of Curcuminoids from Crude Curcumin by a Combination of Crystallization and Chromatography. <i>Organic Process Research and Development</i> , 2017, 21, 821-826.	2.7	36
21	Solubility of the Metastable Polymorph of Piracetam (Form II) in a Range of Solvents. <i>Journal of Chemical & Engineering Data</i> , 2012, 57, 3525-3531.	1.9	35
22	Demonstrating the Influence of Solvent Choice and Crystallization Conditions on Phenacetin Crystal Habit and Particle Size Distribution. <i>Organic Process Research and Development</i> , 2015, 19, 1826-1836.	2.7	35
23	Process Parameters in the Purification of Curcumin by Cooling Crystallization. <i>Organic Process Research and Development</i> , 2016, 20, 1593-1602.	2.7	35
24	Recovery of chromium from tannery effluents using a redox-adsorption approach. <i>Journal of Chemical Technology and Biotechnology</i> , 1995, 62, 30-37.	3.2	34
25	Influence of metal-support interactions on the stability of Ni/SiO ₂ catalysts during cyclic oxidation-reduction treatments. <i>Journal of the Chemical Society Faraday Transactions I</i> , 1984, 80, 3209.	1.0	33
26	Influence of Structurally Related Impurities on the Crystal Nucleation of Curcumin. <i>Crystal Growth and Design</i> , 2018, 18, 4715-4723.	3.0	33
27	Inclusion of the Stable Form of a Polymorph within Crystals of Its Metastable Form. <i>Crystal Growth and Design</i> , 2003, 3, 869-872.	3.0	32
28	Characteristics of a Mesoporous Silicate Immobilized Trypsin Bioreactor in Organic Media. <i>Biotechnology Progress</i> , 2006, 22, 1125-1131.	2.6	30
29	Oxidation of ABTS by Silicate-Immobilized Cytochrome c in Nonaqueous Solutions. <i>Biotechnology Progress</i> , 2008, 19, 1238-1243.	2.6	28
30	Modification of the zeta potential of montmorillonite to achieve high active pharmaceutical ingredient nanoparticle loading and stabilization with optimum dissolution properties. <i>Colloids and Surfaces B: Biointerfaces</i> , 2020, 193, 111120.	5.0	28
31	Measuring the Solubility of a Quickly Transforming Metastable Polymorph of Carbamazepine. <i>Organic Process Research and Development</i> , 2013, 17, 512-518.	2.7	27
32	Understanding the <i>p</i> -Toluenesulfonamide/Triphenylphosphine Oxide Crystal Chemistry: A New 1:1 Cocrystal and Ternary Phase Diagram. <i>Crystal Growth and Design</i> , 2012, 12, 869-875.	3.0	26
33	Dependence of Heterogeneous Nucleation on Hydrogen Bonding Lifetime and Complementarity. <i>Crystal Growth and Design</i> , 2018, 18, 7158-7172.	3.0	19
34	Solution-Mediated Polymorphic Transformation of FV Sulphathiazole. <i>Crystal Growth and Design</i> , 2014, 14, 3466-3471.	3.0	18
35	Experimental Study on the Influence of Excipients on the Heterogeneous Crystallization and Dissolution Properties of an Active Pharmaceutical Ingredient. <i>Crystal Growth and Design</i> , 2018, 18, 338-350.	3.0	18
36	Epitaxial growth of polymorphic systems: The case of sulfathiazole. <i>CrystEngComm</i> , 2011, 13, 5903.	2.6	16

#	ARTICLE	IF	CITATIONS
37	Heterogeneous Crystallization of Fenofibrate onto Pharmaceutical Excipients. <i>Crystal Growth and Design</i> , 2018, 18, 2151-2164.	3.0	14
38	A basis for the kinetic selection of polymorphs during solution crystallization of organic compounds. <i>CrystEngComm</i> , 2018, 20, 5551-5561.	2.6	14
39	Carrier particle mediated stabilization and isolation of valsartan nanoparticles. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019, 175, 554-563.	5.0	14
40	Influence of Process Parameters on the Heterogeneous Nucleation of Active Pharmaceutical Ingredients onto Excipients. <i>Organic Process Research and Development</i> , 2017, 21, 559-570.	2.7	13
41	The heterogeneous crystallization of a novel solvate of clozapine base in the presence of excipients. <i>CrystEngComm</i> , 2018, 20, 4370-4382.	2.6	13
42	Crystal Growth Kinetics of Pharmaceutical Compounds. <i>Crystal Growth and Design</i> , 2020, 20, 7626-7639.	3.0	13
43	Reactions involving electron transfer at semiconductor surfaces. Part 12. "Nature and origins of photoactivity on oxides of 3d transition metals for elimination reactions of secondary alcohols. <i>Journal of the Chemical Society Faraday Transactions I</i> , 1982, 78, 3297.	1.0	11
44	Crystallisation of VOHPO ₄ ·0.5H ₂ O in the presence of a surfactant. <i>Applied Catalysis A: General</i> , 2003, 251, 327-335.	4.3	11
45	Growth kinetics of curcumin form I. <i>CrystEngComm</i> , 2020, 22, 3505-3518.	2.6	10
46	Crystallisation of VOHPO ₄ ·0.5H ₂ O. <i>Applied Catalysis A: General</i> , 2003, 253, 409-416.	4.3	9
47	Phase development and morphology during the thermal treatment of VOHPO ₄ ·0.5H ₂ O. <i>Applied Catalysis A: General</i> , 2005, 285, 36-42.	4.3	9
48	In situ X-ray diffraction studies of the crystallization of VOHPO ₄ ·0.5H ₂ O. <i>Catalysis Today</i> , 2004, 91-92, 185-189.	4.4	6
49	Proteins in Mesoporous Silicates. <i>ACS Symposium Series</i> , 2008, , 49-60.	0.5	5
50	In-situ epoxidation using dioxiranes: evaluation of reactivity and selectivity. <i>Journal of Chemical Technology and Biotechnology</i> , 1998, 72, 60-66.	3.2	4
51	Thermodynamic vs. Kinetic Basis for Polymorph Selection. <i>Processes</i> , 2019, 7, 272.	2.8	4
52	Extended Lifetime of Molecules Adsorbed onto Excipients Drives Nucleation in Heterogeneous Crystallization. <i>Crystal Growth and Design</i> , 2021, 21, 2101-2112.	3.0	4
53	Preparation, stabilisation, isolation and tableting of valsartan nanoparticles using a semi-continuous carrier particle mediated process. <i>International Journal of Pharmaceutics</i> , 2021, 597, 120199.	5.2	4
54	An Investigation into the Adsorption Characteristics of Grafted Mesoporous Silicates for the Removal of Tetramethyl Ammonium Hydroxide from Aqueous Solution. <i>Adsorption Science and Technology</i> , 2002, 20, 787-796.	3.2	2

#	ARTICLE	IF	CITATIONS
55	Studying the impact of the pre-exponential factor on templated nucleation. Faraday Discussions, 2022, 235, 199-218.	3.2	2
56	Effects of structurally related impurities on the crystal growth of curcumin spherulites. CrystEngComm, 2022, 24, 5156-5169.	2.6	2
57	Utilisation of a Mesoporous Silicate Material for the Removal of Quaternary Ammonium Hydroxides (QAHs) from Aqueous Solution. Adsorption Science and Technology, 2002, 20, 261-267.	3.2	1
58	The role of the pre-exponential factor in determining the kinetic selection of polymorphs during solution crystallization of organic compounds. CrystEngComm, 2022, 24, 3088-3095.	2.6	1